ArticleDiscover oncology2025
Identification of copper related biomarkers in breast cancer using machine learning.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBreast cancer is the most prevalent and deadly cancer among women globally, necessitating more effective diagnostic and therapeutic approaches. This study aims to explore new treatment targets and diagnostic tools.
methodsEmploying machine learning techniques and utilizing PCR, IHC technologies, and multiple databases, we identified and validated genes closely linked with breast cancer and copper-induced cell death. We then explored how their expression levels impact cancer diagnosis, prognosis, immune cell infiltration, and drug sensitivity.
resultsThis investigation identified three crucial genes-MT1M, GRHL2, and PKM-intimately associated with the copper death mechanism in breast cancer pathology. Validated through comprehensive analysis across cells, tissue models, and diverse databases, these genes showed significant differential expression (P-value < 0.05), affirming their pivotal role in enhancing diagnostic accuracy (AUC values: 0.917, 0.970, 0.951) and prognostic assessment (HR = 0.65, P = 0.018; HR = 1.69, P = 0.0011; HR = 1.51, P = 0.012) in breast cancer. Additionally, their expression levels influence the infiltration of immune cells and the sensitivity to certain drugs.
conclusionMT1M, GRHL2, and PKM are novel diagnostic and therapeutic targets for breast cancer. These findings enhance prognostic evaluations, deepen our understanding of its mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.